Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Cellectis SA ( (CLLS) ) has provided an announcement.
Cellectis S.A. released its unaudited interim financial report for the first quarter ending March 31, 2025, highlighting the company’s financial position and operational results. The report, prepared according to IAS 34 standards, reflects Cellectis’ ongoing efforts in gene-editing technologies, with a focus on maintaining financial stability and advancing its strategic objectives despite market challenges and regulatory uncertainties.
The most recent analyst rating on (CLLS) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Cellectis SA stock, see the CLLS Stock Forecast page.
Spark’s Take on CLLS Stock
According to Spark, TipRanks’ AI Analyst, CLLS is a Neutral.
Cellectis SA’s stock score is influenced by its strong strategic collaborations, notably with AstraZeneca, which enhance its financial stability and extend its cash runway. However, the company’s ongoing challenges with profitability and mixed technical signals weigh down the overall score. The positive earnings call sentiment and future clinical trial advancements are significant positives, whereas current valuation metrics and profitability issues are key concerns.
To see Spark’s full report on CLLS stock, click here.
More about Cellectis SA
Cellectis S.A. operates in the biotechnology industry, focusing on gene editing technologies and products. The company is known for its development of TALEN® gene-editing technology and works on advancing gene therapies for various medical applications.
Average Trading Volume: 343,625
Technical Sentiment Signal: Sell
Current Market Cap: $112.5M
For detailed information about CLLS stock, go to TipRanks’ Stock Analysis page.